Table of Contents
Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Segment Definitions
1.1.1.1 Procedure segment
1.1.1.2 Product segment
1.1.1.3 Application segment
1.1.1.4 Technology segment
1.1.1.5 End-use segment
1.2 Regional Scope
1.3 Estimates and Forecast Timeline
1.4 Objectives
1.4.1 Objective – 1
1.4.2 Objective – 2
1.4.3 Objective – 3
1.5 Research Methodology
1.6 Information Procurement
1.6.1 Purchased Database
1.6.2 GVR’s Internal Database
1.6.3 Secondary Sources
1.6.4 Primary Research
1.7 Information or Data Analysis
1.7.1 Data Analysis Models
1.8 Market Formulation & Validation
1.9 Model Details
1.9.1 Commodity Flow Analysis
1.10 List of Secondary Sources
1.11 List of Abbreviations
Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Procedure and Product Segment Snapshot
2.3 Application and Technology Segment Snapshot
2.4 End-Use Segment Snapshot
2.5 Competitive Landscape Snapshot
Chapter 3 Global Preimplantation Genetic Testing Market Variables, Trends, and Scope
3.1 Market Lineage Outlook
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.1.1 Rising incidences of genetic diseases
3.2.1.2 Demand for healthy and successful embryo implantation
3.2.1.3 Increase in rate of infertility
3.2.2 Market Restraint Analysis
3.2.2.1 Ethical and legal constraints
3.3 Business Environment Analysis Tools
3.3.1 Porter’s Five Forces Analysis
3.3.2 PESTLE Analysis
3.4 Impact of COVID-19: Qualitative Analysis
Chapter 4 Global Preimplantation Genetic Testing Market – Segment Analysis, by Procedure, 2018 – 2030 (USD Million)
4.1 Global Preimplantation Genetic Testing Market: Procedure Movement Analysis
4.2 Global Preimplantation Genetic Testing Market Estimates & Forecast, By Procedure (USD Million)
4.2.1 PGD
4.2.2 PGS
Chapter 5 Global Preimplantation Genetic Testing Market – Segment Analysis, by Product, 2018 – 2030 (USD Million)
5.1 Global Preimplantation Genetic Testing Market: Product Movement Analysis
5.2 Global Preimplantation Genetic Testing Market Estimates & Forecast, By Product (USD Million)
5.2.1 Reagents & Consumables
5.2.2 Instruments
5.2.3 Software
Chapter 6 Global Preimplantation Genetic Testing Market – Segment Analysis, by Technology, 2018 – 2030 (USD Million)
6.1 Global Preimplantation Genetic Testing Market: Technology Movement Analysis
6.2 Global Preimplantation Genetic Testing Market Estimates & Forecast, By Technology (USD Million)
6.2.1 Next Generation Screening(NGS)
6.2.2 Polymerase Chain Reaction
6.2.3 Fluorescent In-Situ Hybridization (Fish)
6.2.4 Others
Chapter 7 Global Preimplantation Genetic Testing Market – Segment Analysis, by Application, 2018 – 2030 (USD Million)
7.1 Global Preimplantation Genetic Testing Market: Application Movement Analysis
7.2 Global Preimplantation Genetic Testing Market Estimates & Forecast, By Application (USD Million)
7.2.1 Chromosomal Abnormalities
7.2.2 X-Linked Diseases
7.2.3 Embryo Testing
7.2.4 Aneuploidy Screening
7.2.5 HLA Typing
7.2.6 Others
Chapter 8 Global Preimplantation Genetic Testing Market – Segment Analysis, by End-Use, 2018 – 2030 (USD Million)
8.1 Global Preimplantation Genetic Testing Market: End-use Movement Analysis
8.2 Global Preimplantation Genetic Testing Market Estimates & Forecast, By End-use (USD Million)
8.2.1 Fertility Centers
8.2.2 Hospitals
8.2.3 Diagnostic Centers
8.2.4 Research Centers And Academic Labs
Chapter 9 Global Preimplantation Genetic Testing Market: Regional Estimates and Trend Analysis
9.1 Global Preimplantation Genetic Testing Market: Regional Outlook
9.2 North America
9.2.1 North America Preimplantation Genetic Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
9.2.2 U.S.
9.2.2.1 Key Country Dynamics
9.2.2.2 U.S. Preimplantation Genetic Testing Market Estimates and Forecasts, 2018 – 2030 (USD Million)
9.2.2.3 Target Disease Prevalence
9.2.2.4 Competitive Scenario
9.2.2.5 Regulatory Framework
9.1.2.6 Reimbursement Scenario
9.2.3 Canada
9.2.3.1 Key Country Dynamics
9.2.3.2 Canada Preimplantation Genetic Testing Market Estimates and Forecasts, 2018 – 2030 (USD Million)
9.2.3.3 Target Disease Prevalence
9.2.3.4 Competitive Scenario
9.2.3.5 Regulatory Framework
9.2.3.6 Reimbursement Scenario
9.3 Europe
9.3.1 Europe Preimplantation Genetic Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
9.3.2 UK
9.3.2.1 Key Country Dynamics
9.3.2.2 UK Preimplantation Genetic Testing Market Estimates and Forecasts, 2018 – 2030 (USD Million)
9.3.2.3 Target Disease Prevalence
9.3.2.4 Competitive Scenario
9.3.2.5 Regulatory Framework
9.3.2.6 Reimbursement Scenario
9.3.3 Germany
9.3.3.1 Key Country Dynamics
9.3.3.2 Germany Preimplantation Genetic Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
9.3.3.3 Target Disease Prevalence
9.3.3.4 Competitive Scenario
9.3.3.5 Regulatory Framework
9.3.3.6 Reimbursement Scenario
9.3.4 France
9.3.4.1 Key Country Dynamics
9.3.4.2 France Preimplantation Genetic Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
9.3.4.3 Target Disease Prevalence
9.3.4.4 Competitive Scenario
9.3.4.5 Regulatory Framework
9.3.4.6 Reimbursement Scenario
9.3.5 Spain
9.3.5.1 Key Country Dynamics
9.3.5.2 Spain Preimplantation Genetic Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
9.3.5.3 Target Disease Prevalence
9.3.5.4 Competitive Scenario
9.3.5.5 Regulatory Framework
9.3.5.6 Reimbursement Scenario
9.3.6 Italy
9.3.6.1 Key Country Dynamics
9.3.6.2 Italy Preimplantation Genetic Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
9.3.6.3 Target Disease Prevalence
9.3.6.4 Competitive Scenario
9.3.6.5 Regulatory Framework
9.3.6.6 Reimbursement Scenario
9.3.7 Denmark
9.3.7.1 Key Country Dynamics
9.3.7.2 Denmark Preimplantation Genetic Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
9.3.7.3 Target Disease Prevalence
9.3.7.4 Competitive Scenario
9.3.7.5 Regulatory Framework
9.3.7.6 Reimbursement Scenario
9.3.8 Sweden
9.3.8.1 Key Country Dynamics
9.3.8.2 Sweden Preimplantation Genetic Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
9.3.8.3 Target Disease Prevalence
9.3.8.4 Competitive Scenario
9.3.8.5 Regulatory Framework
9.3.8.6 Reimbursement Scenario
9.3.9 Norway
9.3.9.1 Key Country Dynamics
9.3.9.2 Italy Preimplantation Genetic Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
9.3.9.3 Target Disease Prevalence
9.3.9.4 Competitive Scenario
9.3.9.5 Regulatory Framework
9.3.9.6 Reimbursement Scenario
9.4 Asia Pacific
9.4.1 Asia Pacific Preimplantation Genetic Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
9.4.2 Japan
9.4.2.1 Key Country Dynamics
9.4.2.2 Japan Preimplantation Genetic Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
9.4.2.3 Target Disease Prevalence
9.4.2.4 Competitive Scenario
9.4.2.5 Regulatory Framework
9.4.2.6 Reimbursement Scenario
9.4.3 China
9.4.3.1 Key Country Dynamics
9.4.3.2 China Preimplantation Genetic Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
9.4.3.3 Target Disease Prevalence
9.4.3.4 Competitive Scenario
9.4.3.5 Regulatory Framework
9.4.3.6 Reimbursement Scenario
9.4.4 India
9.4.4.1 Key Country Dynamics
9.4.4.2 India Preimplantation Genetic Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
9.4.4.3 Target Disease Prevalence
9.4.4.4 Competitive Scenario
9.4.4.5 Regulatory Framework
9.4.4.6 Reimbursement Scenario
9.4.5 South Korea
9.4.5.1 Key Country Dynamics
9.4.5.2 South Korea Preimplantation Genetic Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
9.4.5.3 Target Disease Prevalence
9.4.5.4 Competitive Scenario
9.4.5.5 Regulatory Framework
9.4.5.6 Reimbursement Scenario
9.4.6 Australia
9.4.6.1 Key Country Dynamics
9.4.6.2 Australia Preimplantation Genetic Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
9.4.6.3 Target Disease Prevalence
9.4.6.4 Competitive Scenario
9.4.6.5 Regulatory Framework
9.4.6.6 Reimbursement Scenario
9.4.7 Thailand
9.4.7.1 Key Country Dynamics
9.4.7.2 Thailand Preimplantation Genetic Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
9.4.7.3 Target Disease Prevalence
9.4.7.4 Competitive Scenario
9.4.7.5 Regulatory Framework
9.4.7.6 Reimbursement Scenario
9.5 Latin America
9.5.1 Latin America Preimplantation Genetic Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
9.5.2 Brazil
9.5.2.1 Key Country Dynamics
9.5.2.2 Brazil Preimplantation Genetic Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
9.5.2.3 Target Disease Prevalence
9.5.2.4 Competitive Scenario
9.5.2.5 Regulatory Framework
9.5.2.6 Reimbursement Scenario
9.5.3 Mexico
9.5.3.1 Key Country Dynamics
9.5.3.2 Mexico Preimplantation Genetic Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
9.5.3.3 Target Disease Prevalence
9.5.3.4 Competitive Scenario
9.5.3.5 Regulatory Framework
9.5.3.6 Reimbursement Scenario
9.5.4 Argentina
9.5.4.1 Key Country Dynamics
9.5.4.2 Argentina Preimplantation Genetic Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
9.5.4.3 Target Disease Prevalence
9.5.4.4 Competitive Scenario
9.5.4.5 Regulatory Framework
9.5.4.6 Reimbursement Scenario
9.6 MEA
9.6.1 MEA Preimplantation Genetic Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
9.6.2 South Africa
9.6.2.1 Key Country Dynamics
9.6.2.2 South Africa Preimplantation Genetic Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
9.6.2.3 Target Disease Prevalence
9.6.2.4 Competitive Scenario
9.6.2.5 Regulatory Framework
9.6.2.6 Reimbursement Scenario
9.6.3 Saudi Arabia
9.6.3.1 Key Country Dynamics
9.6.3.2 Saudi Arabia Preimplantation Genetic Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
9.6.3.3 Target Disease Prevalence
9.6.3.4 Competitive Scenario
9.6.3.5 Regulatory Framework
9.6.3.6 Reimbursement Scenario
9.6.4 UAE
9.6.4.1 Key Country Dynamics
9.6.4.2 UAE Preimplantation Genetic Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
9.6.4.3 Target Disease Prevalence
9.6.4.4 Competitive Scenario
9.6.4.5 Regulatory Framework
9.6.4.6 Reimbursement Scenario
9.6.5 Kuwait
9.6.5.1 Key Country Dynamics
9.6.5.2 Kuwait Preimplantation Genetic Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
9.6.5.3 Target Disease Prevalence
9.6.5.4 Competitive Scenario
9.6.5.5 Regulatory Framework
9.6.5.6 Reimbursement Scenario
Chapter 10 Competitive Landscape
10.1 Company Categorization
10.2 Strategy Mapping
10.2.1 New Product Launch
10.2.2 Partnerships
10.2.3 Acquisition
10.2.4 Collaboration
10.2.5 Funding
10.3 Key Company Market Share Analysis, 2022
10.4 Company Profiles
10.4.1 Quest Diagnostics Incorporated
10.4.1.1 Company Overview
10.4.1.2 Financial Performance
10.4.1.3 Product Benchmarking
10.4.1.4 Strategic Initiatives
10.4.2 Natera, Inc.
10.4.2.1 Company Overview
10.4.2.2 Financial Performance
10.4.2.3 Product Benchmarking
10.4.2.4 Strategic Initiatives
10.4.3 COOPER SURGICAL, Inc.
10.4.3.1 Company Overview
10.4.3.2 Financial Performance
10.4.3.3 Product Benchmarking
10.4.3.4 Strategic Initiatives
10.4.4 Genea Pty Limited.
10.4.4.1 Company Overview
10.4.4.2 Financial Performance
10.4.4.3 Product Benchmarking
10.4.4.4 Strategic Initiatives
10.4.5 Invitae Corporation
10.4.5.1 Company Overview
10.4.5.2 Financial Performance
10.4.5.3 Product Benchmarking
10.4.5.4 Strategic Initiatives
10.4.6 Laboratory Corporation Of America Holdings
10.4.6.1 Company Overview
10.4.6.2 Financial Performance
10.4.6.3 Product Benchmarking
10.4.6.4 Strategic Initiatives
10.4.7 Thermo Fisher Scientific Inc.
10.4.7.1 Company Overview
10.4.7.2 Financial Performance
10.4.7.3 Product Benchmarking
10.4.7.4 Strategic Initiatives
10.4.8 Bioarray S.L.
10.4.8.1 Company Overview
10.4.8.2 Financial Performance
10.4.8.3 Product Benchmarking
10.4.8.4 Strategic Initiatives
10.4.9 Illumina, Inc.
10.4.9.1 Company Overview
10.4.9.2 Financial Performance
10.4.9.3 Product Benchmarking
10.4.9.4 Strategic Initiatives
10.4.10 Igenomix
10.4.10.1 Company Overview
10.4.10.2 Financial Performance
10.4.10.3 Product Benchmarking
10.4.10.4 Strategic Initiatives
10.4.11 RGI
10.4.11.1 Company Overview
10.4.11.2 Financial Performance
10.4.11.3 Product Benchmarking
10.4.11.4 Strategic Initiatives
10.4.12 F. Hoffmann-La Roche Ltd
10.4.12.1 Company Overview
10.4.12.2 Financial Performance
10.4.12.3 Product Benchmarking
10.4.12.4 Strategic Initiatives
Chapter 11 Conclusion
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/